Effectiveness of first-generation HCV protease inhibitors: Does HIV coinfection still play a role?

European Journal of Gastroenterology and Hepatology

Volumn 28, Issue 1, 2016, Pages 37-41

  Nicolini, Laura A ^a   Menzaghi, Barbara ^b   Ricci, Elena ^c   Martinelli, Canio ^d   Magni, Carlo ^c   Maggi, Paolo ^e   Celesia, Benedetto M ^f   Parruti, Giustino ^g   Babudieri, Sergio ^h   Bonfanti, Paolo ⁱ   Falasca, Katia ^j   Vichi, Francesca ^k   De Socio, Giuseppe V ^l   Salomoni, Elena ^d   Di Biagio, Antonio ^a   Quirino, Tiziana ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b BUSTO ARSIZIO HOSPITAL   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d CAREGGI UNIVERSITY HOSPITAL   (Italy)

^e UNIVERSITY OF BARI   (Italy)

^f UNIVERSITY OF CATANIA   (Italy)

^g SPIRITO SANTO HOSPITAL   (Italy)

^h UNIVERSITY OF SASSARI   (Italy)

ⁱ A MANZONI HOSPITAL   (Italy)

^j UNIVERSITY OF CHIETI   (Italy)

^k SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^l Santa Maria Hospital   (Italy)

more..

Author keywords

Boceprevir; Direct active agent; Effectiveness; Hepatitis C virus; HIV; Protease inhibitors; Sustained virologic response; Telaprevir

Indexed keywords

BOCEPREVIR; TELAPREVIR; ANTIVIRUS AGENT; INTERFERON; MACROGOL DERIVATIVE; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; OLIGOPEPTIDE; PROLINE; PROTEINASE INHIBITOR; RIBAVIRIN; VIRUS RNA;

ADULT; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; ASTHENIA; CD4 LYMPHOCYTE COUNT; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ERADICATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ITALY; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MIDDLE AGED; MIXED INFECTION; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SKIN MANIFESTATION; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; COINFECTION; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERONS; MALE; MIDDLE AGED; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PROLINE; PROSPECTIVE STUDIES; PROTEASE INHIBITORS; RIBAVIRIN; RNA, VIRAL; VIRAL LOAD;

EID: 84983122115     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000483     Document Type: Article

References (35)

1. Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360:1839-1850.
2. McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362:1292-1303.
3. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-2416.
4. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1207-1217.
5. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195-1206.
6. FDA. Press announcements-FDA approves Victrelis for hepatitis C [Internet]. Available at: http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm255390.htm. [Accessed 6 June 2015].
7. Tural C, Galeras JA, Planas R, Coll S, Sirera G, Giménez D, et al. Differences in virological response to pegylated interferon and ribavirin between hepatitis C virus (HCV)-monoinfected and HCV-HIV-coinfected patients. Antivir Ther 2008; 13:1047-1055.
8. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438-450.
9. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-355.
10. Cotte L, Braun J, Lascoux-Combe C, Vincent C, Valantin M-A, Sogni P, et al. Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial. Clin Infect Dis 2014; 59:1768-1776.
11. Sulkowski M, Pol S, Mallolas J, Fainboim H, Cooper C, Slim J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis 2013; 13:597-605.
12. EASL. EASL-clinical practice guidelines [Internet]. Available at: http:// www.easl.eu/research/our-contributions/clinical-practice-guidelines/ detail/recommendations-on-treatment-of-hepatitis-c-2015. [Accessed 6 June 2015].
13. Genebat M, Vera F, Hernández-Quero J, Domingo P, Guardiola JM, Martínez-Madrid O, et al. Efficacy and tolerability after 24 weeks of treatment with telaprevir, pegylated interferon and ribavirin in cirrhotic HIV-HCV coinfected subjects. Antiviral Res 2014; 104:59-61.
14. Martel-Laferrière V, Brinkley S, Bichoupan K, Posner S, Stivala A, Perumalswami P, et al. Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection. HIV Med 2014; 15:108-115.
15. Lacombe K, Valin N, Stitou H, Gozlan J, Thibault V, Boyd A, et al. Efficacy and tolerance of telaprevir in HIV-hepatitis C virus genotype 1-coinfected patients failing previous antihepatitis C virus therapy: 24-week results. AIDS Lond Engl 2013; 27:1356-1359.
16. CISAI. Coordinamento Italiano Studio Allergie e Infezione da HIV [Internet]. Available at: https://www.cisai.info/new/index.html. [Accessed 6 June 2015].
17. Bonfanti P, Martinelli C, Ricci E, Carradori S, Parruti G, Armignacco O, et al. An Italian approach to postmarketing monitoring: preliminary results from the SCOLTA (Surveillance Cohort Long-Term Toxicity Antiretrovirals) project on the safety of lopinavir/ritonavir. J Acquir Immune Defic Syndr 2005; 39:317-320.
18. National Institute of Allergy and Infectious Diseases. Division of AIDS table for grading the severity of adult and pediatric adverse events [Internet], 2004. Available at: http://www.niaid.nih.gov/labsandresources/resources/daidsclinrsrch/documents/daidsaegradingtable.pdf. [Accessed 6 June 2015].
19. WHO-UMC. The use of the WHO-UMC system for standardised case causality assessment [Internet], 2005. Available at: http://who-umc.org/ Graphics/24734.pdf. [Accessed 10 June 2015].
20. Neukam K, Munteanu DI, Rivero-Juárez A, Lutz T, Fehr J, Mandorfer M, et al. Boceprevir or telaprevir based triple therapy against chronic hepatitis C in HIV coinfection: real-life safety and efficacy. PloS One 2015; 10:e0125080.
21. Miailhes P, Gilbert C, Lacombe K, Arends JE, Puoti M, Rockstroh JK, et al. Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1-coinfected patients. Liver Int 2015; 35:2090-2099.
22. Vo KP, Vutien P, Akiyama MJ, Vu VD, Ha NB, Piotrowski JI, et al. Poor sustained virological response in a multicenter real-life cohort of chronic hepatitis C patients treated with pegylated interferon and ribavirin plus telaprevir or boceprevir. Dig Dis Sci 2015; 60:1045-1051.
23. Beisel C, Heuer M, Otto B, Jochum J, Schmiedel S, Hertling S, et al. German cohort of HCV mono-infected and HCV/HIV co-infected patients reveals relative under-treatment of co-infected patients. AIDS Res Ther 2014; 11:16.
24. Soria A, Limonta S, Leone S, Muscatello A, Squillace N, Bandera A, et al. Similar success rates but lower incidence of telaprevir-related rash in HIV/HCV coinfected as compared to HCV-monoinfected patients treated with triple anti-HCV therapy. J Acquir Immune Defic Syndr 2015; 69:e37-e40.
25. Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356:1800-1805.
26. De Luca A, Bugarini R, Lepri AC, Puoti M, Girardi E, Antinori A, et al. Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. Arch Intern Med 2002; 162:2125-2132.
27. Piroth L, Grappin M, Cuzin L, Mouton Y, Bouchard O, Raffi F, et al. Hepatitis C virus co-infection is a negative prognostic factor for clinical evolution in human immunodeficiency virus-positive patients. J Viral Hepat 2000; 7:302-308.
28. Herrero-Martínez E, Sabin CA, Evans JG, Griffioen A, Lee CA, Emery VC. The prognostic value of a single hepatitis C virus RNA load measurement taken early after human immunodeficiency virus seroconversion. J Infect Dis 2002; 186:470-476.
29. Dorrucci M, Valdarchi C, Suligoi B, Zaccarelli M, Sinicco A, Giuliani M, et al. The effect of hepatitis C on progression to AIDS before and after highly active antiretroviral therapy. AIDS 2004; 18:2313-2318.
30. Braitstein P, Zala C, Yip B, Brinkhof MWG, Moore D, Hogg RS, et al. Immunologic response to antiretroviral therapy in hepatitis C viruscoinfected adults in a population-based HIV/AIDS treatment program. J Infect Dis 2006; 193:259-268.
31. Pulido F, Hill A, van Delft Y, Moecklinghoff C. Impact of hepatitis C coinfection on response to antiretroviral treatment. AIDS Rev 2012; 14:124-131.
32. Hua L, Andersen JW, Daar ES, Glesby MJ, Hollabaugh K, Tierney C. Hepatitis C virus/HIV coinfection and responses to initial antiretroviral treatment. AIDS 2013; 27:2725-2734.
33. Lincoln D, Petoumenos K, Dore GJ. Australian HIV observational database. HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy. HIV Med 2003; 4:241-249.
34. Grint D, Peters L, Rakmanova A, Rockstroh JK, Karpov I, Galli M, et al. Liver-related death among HIV/HCV coinfected individuals, implications for the era of directly acting antivirals. Boston, MA; 2014. Available at: http://www.cphiv.dk/portals/0/files/CROI-2014-EuroSIDA-Grint-Wed 22.00.pdf.
35. Berenguer J, Rodríguez E, Miralles P, Von Wichmann MA, López-Aldeguer J, Mallolas J, et al. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis 2012; 55:728-736.